Impact of Smoking, Benzodiazepine (BZD) Use and Obesity on Severe Obstructive Sleep Apnea (sOSA)
NCT ID: NCT02539264
Last Updated: 2016-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
920 participants
OBSERVATIONAL
2014-01-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Tobacco Smoking on the Development of Obstructive Sleep Apnea (OSA)
NCT03574740
Weight Loss and Obstructive Sleep Apnea
NCT02206126
The Effects of Trazodone on Sleep Apnea Severity
NCT01817907
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)
NCT01620554
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome
NCT05245240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
First analysis: influence of smoking, benzodiazepine use, and obesity on the AHI (Apnea Hypopnea Index: the number of apnea and hypopnea per hour of sleep).
Second analysis: only among patients with sOSA: influence of smoking, benzodiazepine use, and obesity on sleep fragmentation and night oximetry.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smoking
Influence of smoking on parameters derived from overnight PSG
Obesity
Influence of obesity on parameters derived from overnight PSG
Benzodiazepine use
Influence of benzodiazepine use on parameters derived from overnight PSG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric DEFLANDRE, MD, FCCP
MD, FCCP
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric DEFLANDRE, MD, FCCP
Role: PRINCIPAL_INVESTIGATOR
Astes
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEES-OSA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.